Tecentriq-Abraxane Combo OK’d in EU to Treat Certain Advanced Triple-negative Breast Cancers

Tecentriq-Abraxane Combo OK’d in EU to Treat Certain Advanced Triple-negative Breast Cancers
The European Commission has approved the use of Roche's Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) chemotherapy to treat certain adults with advanced triple-negative breast cancer (TNBC), an aggressive and difficult-to-treat malignancy. The combo is intended for people whose tumors cannot be removed by surgery  (unresectable), are locally advanced or metastatic (spread to other parts in the body), and are positive for the PD-L1 factor. This combination therapy is also intended for patients who have not received prior chemotherapy for metastatic breast cancer. Given accelerated approval by U.S. Food and Drug Administration in March, Tecentriq-Abraxane now becomes the first cancer immunotherapy regimen available in Europe specifically for TNBC. “For the past 30 years, we have been dedicated to transforming the lives of people with breast cancer. Now, we are pleased to build on this foundation with the news that the first immunotherapy treatment for triple-negative breast cancer is available to people in Europe with PD-L1-positive, metastatic triple-negative breast cancer,” Sandra Horning, MD, Roche’s chief medical officer and head of global product develop
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.